Literature DB >> 8076350

Comparative study of radiation-induced G2 phase delay and chromatid damage in families with ataxia-telangiectasia.

P Chen1, A Farrell, K Hobson, A Girjes, M Lavin.   

Abstract

Two assay systems, radiation-induced chromosome aberrations and flow cytometry, were compared for the detection of ataxia-telangiectasia (A-T) heterozygotes. In three A-T families, the frequencies of chromatid aberrations in phytohemagglutinin-stimulated blood lymphocytes after 1 Gy of gamma-irradiation were twofold higher in A-T homozygotes than in obligate A-T heterozygotes, which were in turn approximately twofold higher than in normal control cells. Other consanguineous relatives of A-T patients had intermediate levels of induced chromatid aberrations, suggesting that they were carriers of the gene. Matched Epstein-Barr virus-transformed lymphoblastoid cell lines from A-T homozygotes showed a greater radiation-induced accumulation in the G2 phase of the cell cycle than did control cells. In family B, both obligate heterozygotes had increased G2 delay, as did the one heterozygote available for family C, and two of the grandparents in that family were in the high range for G2 delay. Neither parent in family A had high G2 phase delay after irradiation although the induced chromatid aberrations were in the heterozygote valve range. These results show a good concordance between the two assay systems for A-T heterozygotes, with the chromatid aberrations somewhat more consistent.

Entities:  

Mesh:

Year:  1994        PMID: 8076350     DOI: 10.1016/0165-4608(94)90069-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Role of the ataxia-telangiectasia gene (ATM) in breast cancer. A-T heterozygotes seem to have an increased risk but its size is unknown.

Authors:  M Lavin
Journal:  BMJ       Date:  1998-08-22

Review 2.  Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells.

Authors:  H D Lohrer
Journal:  Experientia       Date:  1996-04-15

3.  Low levels of ATM in breast cancer patients with clinical radiosensitivity.

Authors:  Zhiming Fang; Sergei Kozlov; Michael J McKay; Rick Woods; Geoff Birrell; Carl N Sprung; Dédée F Murrell; Kiran Wangoo; Linda Teng; John H Kearsley; Martin F Lavin; Peter H Graham; Raymond A Clarke
Journal:  Genome Integr       Date:  2010-06-24

4.  Variant ataxia telangiectasia: clinical and molecular findings and evaluation of radiosensitive phenotypes in a patient and relatives.

Authors:  Kathleen Claes; Julie Depuydt; A Malcolm R Taylor; James I Last; Annelot Baert; Peter Schietecatte; Veerle Vandersickel; Bruce Poppe; Kim De Leeneer; Marc D'Hooghe; Anne Vral
Journal:  Neuromolecular Med       Date:  2013-04-30       Impact factor: 3.843

5.  Individual Radiosensitivity Assessment of the Families of Ataxia-Telangiectasia Patients by G2-Checkpoint Abrogation.

Authors:  Asghar Aghamohammadi; Seyed M Akrami; Marjan Yaghmaie; Nima Rezaei; Gholamreza Azizi; Mehdi Yaseri; Hassan Nosrati; Majid Zaki-Dizaji
Journal:  Sultan Qaboos Univ Med J       Date:  2019-03-28

6.  Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers.

Authors:  M Fernet; N Moullan; A Lauge; D Stoppa-Lyonnet; J Hall
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.